Aventis Pharmaceuticals and ViroPharma form U.S. Co-Promotion And Co-Development Collaboration
Picovir™ works by specifically inhibiting the function of the picornavirus capsid, a protective shell of the virus that is essential for virus infectivity and transmission. Picornaviruses are the primary cause of viral respiratory infection. ViroPharma submitted a new drug application to the U.S. Food and Drug Administration on July 31, 2001, seeking approval for the use of Picovir™ to treat VRI in adults.
As part of the agreement, ViroPharma receives an initial payment of $25 million from Aventis. ViroPharma will also receive cash payments from Aventis based upon the achievement of certain milestones. Each of the payments is dependent upon reaching certain regulatory and other milestones. If Picovir™ is approved by the FDA, Aventis will distribute and record revenues from sales of Picovir™, and both companies will share profits; 55 percent to Aventis and 45 percent to ViroPharma. ViroPharma will co-promote certain Aventis Pharmaceuticals prescription products to primary care physicians in the United States, and will receive detailing fees from Aventis for such calls.
According to the National Institutes of Health, there are approximately 1 billion colds annually in the United States. Currently, 52 million physician visits are attributable to patients with VRI, yet there are no antiviral treatments available for these patients. Patients often take a variety of prescription or over-the-counter medications for VRI, however these medications do not treat the underlying cause of the disease, the virus.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.